# EDGAR Filing Document

**Accession Number:** 0001843762
**File Stem:** 0000000000-23-002079
**Filing Date:** 2023-3
**Character Count:** 3303
**Document Hash:** 1d8605e3e389e79892f2fd2b1f561c1d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-23-002079.hdr.sgml**: 20230331

**ACCESSION NUMBER**: 0000000000-23-002079

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230301

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** EQRx, Inc.
- **CENTRAL INDEX KEY:** 0001843762
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 861691173
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD

**BUSINESS ADDRESS:**
- **STREET 1:** 50 HAMPSHIRE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** (617) 315-2255

**MAIL ADDRESS:**
- **STREET 1:** 50 HAMPSHIRE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CM Life Sciences III Inc.
- **DATE OF NAME CHANGE:** 20210201
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-23-024837

## Text-Extract

```

United States securities and exchange commission logo

                          March 1, 2023

       Melanie Nallicheri
       Chief Executive Officer
       EQRx, Inc.
       50 Hampshire Street
       Cambridge, Massachusetts 02139

                                                        Re: EQRx, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed February 23,
2023
                                                            File No. 333-269973

       Dear Melanie Nallicheri:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Alan
Campbell at 202-551-4224 with any questions.

                          Sincerely,

                          Division of Corporation Finance

                          Office of Life Sciences
       cc:                                              Marianne Sarrazin

```

### Attached PDF Documents

**Attachment 1:** `filename1`

![img-0.jpeg](img-0.jpeg)

DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

March 1, 2023

Melanie Nallicheri
Chief Executive Officer
EQRx, Inc.
50 Hampshire Street
Cambridge, Massachusetts 02139

**Re: EQRx, Inc.**
**Registration Statement on Form S-3**
**Filed February 23, 2023**
**File No. 333-269973**

Dear Melanie Nallicheri:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Marianne Sarrazin